NCT06573593View on ClinicalTrials.gov

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Alopecia AreataJanus Kinase Inhibitors
Interventions
DRUG

Tofacitinib

In the real-world settings, patients with AA treated with tofacitinib.

DRUG

Baricitinib

In the real-world settings, patients with AA treated with Baricitinib.

DRUG

Ruxolitinib

In the real-world settings, patients with AA treated with Ruxolitinib.

DRUG

Upadacitinib

In the real-world settings, patients with AA treated with Upadacitinib.

DRUG

Abrocitinib

In the real-world settings, patients with AA treated with Abrocitinib.

DRUG

Ritlecitinib

In the real-world settings, patients with AA treated with Ritlecitinib.

Trial Locations (1)

310009

RECRUITING

Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER